1. Home
  2. ESGL vs THAR Comparison

ESGL vs THAR Comparison

Compare ESGL & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ESGL

ESGL Holdings Limited

HOLD

Current Price

$3.40

Market Cap

169.6M

Sector

N/A

ML Signal

HOLD

Logo Tharimmune Inc.

THAR

Tharimmune Inc.

HOLD

Current Price

$4.70

Market Cap

193.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESGL
THAR
Founded
1999
2017
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
169.6M
193.3M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
ESGL
THAR
Price
$3.40
$4.70
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
10.7K
1.2M
Earning Date
03-03-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,328,277.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$0.95
52 Week High
$4.32
$9.08

Technical Indicators

Market Signals
Indicator
ESGL
THAR
Relative Strength Index (RSI) 18.47 66.15
Support Level $3.19 $2.71
Resistance Level $3.62 $5.83
Average True Range (ATR) 0.19 0.50
MACD -0.04 0.21
Stochastic Oscillator 25.93 63.46

Price Performance

Historical Comparison
ESGL
THAR

About ESGL ESGL Holdings Limited

ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Share on Social Networks: